photo of Dr Henry Beetham

Dr Henry Beetham

Dr Henry Beetham

Details

Role Senior Research Officer
Group Stafford Fox Drug Discovery Facility
.
.

Top Publications

  • Beetham, H, Griffith, BGC, Murina, O, Loftus, AEP, Parry, DA, Temps, C, Culley, J, Muir, M, Unciti-Broceta, A, Sims, AH, et al. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC InhibitorsLoss of ILK Sensitizes Breast Cancer to SRC Inhibitors. Cancer Research 82(4) : 632 -647 2022
    view publication
  • Luxenburger, A, Bougen-Zhukov, N, Fraser, MG, Beetham, H, Harris, LD, Schmidt, D, Cameron, SA, Guilford, PJ, Evans, GB. Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer. Journal of Medicinal Chemistry 64(24) : 18114 -18142 2021
    view publication
  • Temps, C, Lietha, D, Webb, ER, Li, X-F, Dawson, JC, Muir, M, Macleod, KG, Valero, T, Munro, AF, Contreras-Montoya, R, et al. A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and TolerabilityNew Mode of Inhibiting SRC Improves Drug Properties. Cancer Research 81(21) : 5438 -5450 2021
    view publication
  • Beetham, H, Chen, A, Telford, BJ, Single, A, Jarman, KE, Lackovic, K, Luxenburger, A, Guilford, P. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.. Sci Rep 9(1) : 12511 2019
    view publication
  • Godwin, TD, Kelly, ST, Brew, TP, Bougen-Zhukov, NM, Single, AB, Chen, A, Stylianou, CE, Harris, LD, Currie, SK, Telford, BJ, et al. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. Gastric Cancer 22(2) : 273 -286 2019
    view publication

Page 1 of 3